Search company, investor...

AmpliMed

amplimed.com

Founded Year

1989

Stage

Series D | Alive

Total Raised

$41.49M

Valuation

$0000 

Last Raised

$3.9M | 13 yrs ago

About AmpliMed

AmpliMed Corporation, a clinical-stage pharmaceutical company founded by oncologists, is focused on a lead compound, Amplimexon, which per AmpliMed has shown early evidence of efficacy and low levels of toxicity. The company is focused on the development of small-molecule oncology drugs with novel mechanisms of action.

Headquarters Location

4380 North Campbell Avenue Suite 205

Tucson, Arizona, 85718,

United States

520-529-1000

Missing: AmpliMed's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: AmpliMed's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing AmpliMed

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AmpliMed is included in 2 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest AmpliMed News

Startup Amplimed fornece telemedicina com prontuário eletrônico para o Sistema Unimed SP

Sep 22, 2020

Terça, 22 Setembro 2020 18:21 Escrito ou enviado por Tatiana Diniz O médico Marcos Sonagli e os empreendedores Liandro Segalin e Darlan Segalin, fundadores da Amplimed A startup Amplimed fechou contrato com a Unimed Fesp para fornecer o serviço de prontuário eletrônico e telemedicina ao Sistema Unimed no Estado de São Paulo. A inovação também foi adotada pelas Unimeds Cuiabá e Blumenau e deve chegar a outras cidades brasileiras em breve. Com a parceria, os profissionais de saúde credenciados pela rede Unimed passam a oferecer o serviço de teleorientação a seus pacientes, contribuindo diretamente para as medidas de isolamento social necessárias ao controle da pandemia do novo coronavírus. A Unimed Fesp, de acordo com seu presidente Dr. Omar Abujamra Junior, vem se preparando desde março de 2019 para o uso da telemedicina, sempre em acordo com a legislação vigente e regras das entidades de classe e do Sistema Unimed, respeitando clientes e médicos cooperados.“A plataforma segue critérios de segurança e de integração com outras ferramentas disponibilizadas pelo Hub VitALL, como a biometria facial para médicos e pacientes, e está sendo disponibilizada a todas as Unimeds do estado de São Paulo, além de outros estados por meio de parcerias. Viabilizamos, também, ferramentas para a capacitação dos cooperados e parceria com uma empresa para certificados digitais. A Amplimed está em processo de implantação em mais de 15 cooperativas Unimeds, e a expectativa é de gerenciar o sistema das clínicas de mais de 2.000 mil médicos”, explicou o dirigente. Por conta do seu grau de inovação, a plataforma Amplimed foi uma das selecionadas entre 200 startups inscritas para o programa de aceleração Conexão Vitall, promovido pela Unimed Fesp, por meio do hub Vitall, e realizado em parceria com a Liga Ventures.“A expectativa era que se tivesse um software para todo o estado e a Amplimed superou as expectativas liberando a telemedicina para as Unimeds de uma forma muito rápida”, acrescenta Alisson Valerio, padrinho da Amplimed no processo de aceleração e gerente de TI da Unimed São José dos Campos. “O programa foi fundamental por uma questão de gestão de negócios, de parceria, de mentoria e de aceleração como um todo. Acabamos nos tornando o prontuário-referência”, comenta Dr. Marcos A. Sonagli, diretor médico da Amplimed. Diante da pandemia, a ferramenta de telemedicina foi lançada já no início da quarentena do Estado de São Paulo. A plataforma de prontuário eletrônico roda em nuvem e já inclui diversos módulos de especialidades médicas: ginecologia, pediatria, reumatologia, oncologia, oftalmologia e dermatologia, entre outras, além de ferramentas de confirmação automática de consultas e prescrição digital de medicamentos. Outra vantagem é garantir a segurança dos dados de acordo com as melhores práticas do mercado e novas normas da nova Lei Geral de Proteção de Dados (LGPD), além de cumprir as normas do país para a realização de consultas médicas (CFM e ICP-Brasil). Sobre a Unimed Fesp A Unimed Fesp tem dois papéis. É a 16ª operadora de plano de saúde do País, com mais de 500 mil beneficiários ao mesmo tempo que representa institucionalmente os interesses de 76 Unimeds filiadas no estado de São Paulo, que administram 20 mil médicos, 40 hospitais, 38 mil colaboradores, 30 unidades de Atenção Primária à Saúde, quatro Hospitais Dia, 68 Pronto Atendimento, 38 Centros de Diagnóstico, 31 laboratórios, 33 Farmácias e sete Óticas. Sobre a Amplimed Amplimed é a primeira plataforma online para gestão de clínicas e consultórios com teleconsultas integradas. Foi criada em 2015 em Santa Catarina na cidade de Chapecó, pelos empreendedores Darlan Segalin, Liandro Segalin e pelo médico ortopedista Dr. Marcos Sonagli, a partir de uma necessidade percebida na clínica médica. A HealthTech (startup voltada à área de saúde) recebeu aporte da Oxigênio Aceleradora, parceria da Porto Seguro com a Plug and Play Tech Center, uma das maiores aceleradoras do Vale do Silício. Atualmente a plataforma está presente em mais de 670 clínicas e é usada por mais de 8.500 profissionais em todo o Brasil. Compartilhe::Participe do GRUPO SEGS - PORTAL NACIONAL no FACEBOOK...:

AmpliMed Frequently Asked Questions (FAQ)

  • When was AmpliMed founded?

    AmpliMed was founded in 1989.

  • Where is AmpliMed's headquarters?

    AmpliMed's headquarters is located at 4380 North Campbell Avenue, Tucson.

  • What is AmpliMed's latest funding round?

    AmpliMed's latest funding round is Series D.

  • How much did AmpliMed raise?

    AmpliMed raised a total of $41.49M.

  • Who are the investors of AmpliMed?

    Investors of AmpliMed include Solstice Capital, Valley Ventures, Biotech Insight Venture Partners, Investbio, Village Ventures and 4 more.

  • Who are AmpliMed's competitors?

    Competitors of AmpliMed include Cellworks, Stemina Biomarker Discovery, Alfama, Santaris Pharma, NeurOP and 12 more.

Compare AmpliMed to Competitors

E
Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

Stemina Biomarker Discovery Logo
Stemina Biomarker Discovery

Stemina Cell Discovery discovers and validates small molecules as biomarkers for high-throughput drug screening and disease diagnostics using an all human system comprised of stem cells and the company's metabolomics platform. Metabolomics aims to enable the discovery of small molecules that can be used as candidate biomarkers of disease and pharmacological efficacy or toxicity. The human embryonic stem cell metabolome is a source of candidate biomarkers to predict, diagnose or measure the progress of disease or toxic response. Stemina aims to provide compound screening and diagnostic development for the pharmaceutical and biotechnology industries and academia under contract services or joint discovery agreements.

N
NeurOP

NeurOp is a biopharmaceutical company developing new medicines to treat central nervous system disorders, including major depression, neuropathic pain and ischemia. The company's mission is to develop a new generation of N-methyl-D-aspartate (NMDA) receptor blockers, which inhibit proteins that play an important role in neuron signaling. Its compounds specifically target the NR2B subtype of these receptors offering an unprecedented opportunity to improve the safety and tolerability of this therapeutic class without compromising efficacy.

H
Humanetics

Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

Cellworks Logo
Cellworks

Cellworks Group specializes in Personalized Medicine in the key therapeutic areas of Oncology and Immunology. Using multi-omics modeling, computational biosimulation, and Artificial Intelligence heuristics, Cellworks predicts efficacious therapies for patients. The Cellworks unique biosimulation platform is a unified representation of biological knowledge curated from heterogeneous datasets and applied to finding cures. The company is based in South San Francisco, California, and has a research and development facility in Bangalore, India.

P
Psimei Pharmaceutical

Psimei Pharmaceuticals is developing boron-based drugs for applications in Photon Activation Therapy (PAT). This involves the use of standard radiotherapy to activate boron-based compounds which selectively target solid tumours. This results in an amplification of the therapeutic effect of conventional radiotherapy. Pre-clinical data for Psimei's lead product, PP200PAT, has demonstrated 90% true cure rates at 6 months in tumour models compared with 30% for conventional radiotherapy alone. It also enabled much shorter treatment regimes - days as opposed to weeks. This drug is being prepared for clinical development.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.